The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1552-1561

  Baruch, Amos ^a   Hartmann, Mor Li ^a   Yoeli, Merav ^a   Adereth, Yair ^a   Greenstein, Shulamit ^a   Stadler, Yona ^b   Skornik, Yehuda ^b   Zaretsky, Joseph ^a   Smorodinsky, Nechama I ^a   Keydar, Iafa ^a   Wreschner, Daniel H ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN;

ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

EID: 0033119025     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Szabo, C. I., and King, M. C. Inherited breast and ovarian cancer. Hum. Mol. Genet., 4: 1811-1817, 1995.
2. Burchell, J., Gendler, S., Tayor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., and Lamport, D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47: 5476-5482, 1987.
3. Ceriani, R. L., Chan, C. M., Baratta, F. S., Ozzello, L., DeRosa, C. M., and Habif, D. V. Levels of expression of hreast epithelial mucin detected by monoclonal antibody BrE-3 in hreast cancer prognosis. Int. J. Cancer, 51: 343-354, 1992.
4. Laurence, V., Forties, M. A., and Cooper, E. H. Use of mucin like cancer associated antigen (MCA) in the management of hreast cancer. Br. J. Cancer, 63: 1000-1004, 1991.
5. Linsley, P. S., Brown, J. P., Magnani, J. L., and Horn, D. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res., 48: 2138-2148, 1988.
6. MacLean, G. D., Reddish, M. A., and Longenecker, B. M. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metaslatic adenocarcinoma patients. J. Immunother., 20: 70-78, 1997.
7. McGuckin, M. A., Walsh, M. D., Hohn, B. G., Ward, B. G., and Wright, R. G. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum. Pathol., 26: 432-439, 1995.
8. Muller-Brand, J., and Macke, H. Clinical significance of the new tumor marker MCA in the follow-up of patients with mammary carcinoma. Int. J. Biol. Markers, 8: 130-132, 1993.
9. Xing, P. X., Prenzoska, J., Quelch, K., and McKenzie, I. F. C. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res., 52: 2310-2317, 1992.
10. Wreschner, D. H., Hareuveni, M., Tsarfaty, I., Smorodinsky, N., Horev, J., Zaretsky, J., Kotkes, P., Weiss, M., Lathe, R., Dion, A. S., and Keydar. I. Human epithelial tumor antigen cDNA sequences - differential splicing may generate multiple protein forms. Eur. J. Biochem., 189: 463-473, 1990.
11. Ligtenberg, M. J. L., Vos, H. L., Genissen, A. M. C., and Hilkens, J. Episialin, a carcinoma associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J. Biol. Chem., 265: 15573-15578, 1990.
12. Gendler, S. J., Lancaster, C. A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burcheli, J., Pemberton, L., Lalani, E-N., and Wilson, D. Molecular cloning and expression of the human tumor associated polymorphic epithelial mucin PEM. J. Biol. Chem., 265: 15286-15293, 1990.
13. Abe, M., and Kufe, D. Characterization of cis-acting elements regulating transcription of the human DF3 hreast carcinoma-associated antigen (MUC1) gene. Proc. Natl. Acad. Sci. USA, 90: 282-286, 1993.
14. Hilkens, J., Ligtenberg, M. J-L., Vos, H. L., and Litvinov, S. V. Cell membrane associated mucins and their adhesion modulating properly. Trends Biochem. Sci., 17: 359-363, 1992.
15. Ligtenberg, M. J. L., Kruijshaar, L., Buijs, F., Van Meijer, M., Litvinov, S. V., and Hilkens, J. Cell associated episialin is a complex containing two proteins derived from a common precursor. J. Biol. Chem., 267: 6171-6177, 1992.
16. Boshell, M., Lanani, E. N., Pemberton, L., Burchell, J., Gendler, S., and Taylor-Papadimitriou, J. The product of the human MUC1 gene when secreted by mouse cells transfected with the full-length cDNA lacks the cytoplasmic tail. Biochem. Biophys. Res. Commun., 185: 1-8, 1992.
17. Smorodinsky, N., Weiss, M., Harlman, M., Baruch, A., Harness, E., Yaakobovits, M., Keydar, I., and Wreschner D. H. Detection of a secreted MUC1/SEC protein by MUC1/SEC specific monoclonal antibodies Biochem. Biophys. Res. Commun., 228: 115-121, 1996.
18. Ligtenberg, M. J., Buijs, F., Vos, H. L., and Hilkens, J. Suppression of cellular aggregation by high levels of episialin. Cancer Res., 52: 2318-2324, 1992.
19. Hartman, M., Tsarfaty, I., Hareuveni, M., Keydar, I., and Wreschner, D. H. Expression of breast cancer mucin, MUC1, alters cell adhesion and a MUC1 variant may act as a receptor molecule on breast cancer cells. In: L. Ioanndou-Mouzaka, N. J. Agnantis, and I. Karydas (eds.), Senology: Proceedings of the 7th International Congress on Senology, pp. 379-383. Amsterdam: Excerpta Medica Publishers, 1992.
20. Wesseling, J., van der Valk, S. W., Vos, H. L., Sonnenberg, A., and Hilkens, J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol., 129: 255-265, 1995.
21. Spicer, A. P., Rowse, G. J., Lidner, T-K., and Gendler, S. J. Delayed mammary tumor progression in MUC-1 null mice J. Biol. Chem., 270: 30093-30101, 1995.
22. Zrihan-Licht, S., Vos, H. L., Baruch, A., Elroy-Stein, O., Sagiv, D., Keydar, I., Hilkens, J., and Wreschner D. H. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissues. Eur. J. Biochem. 224: 787-795, 1994.
23. Hartman, M., Baruch, A., Ron, I., Adereth, Y., Yoeli, M., Sagi-Assif, O., Greenstein, S., Stadler, Y., Weiss, M., Harness, E., Yaakubovits, M., Keydar, I., Smorodinsky, N., and Wreschner D. H. The MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast cancer and other epithelial malignancies. Int. J. Cancer, in press, 1999.
24. Baruch, A., Hartman, M., Zrihan-Licht, S., Greenstein S., Burstein, M., Keydar, I., Weiss, M., Smorodinsky, N., and Wreschner D. H. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor potentiating function. Int. J. Cancer. 71: 741-749, 1997.
25. Zrihan-Licht, S., Baruch, A., Elroy-Stein, O., Keydar, I., and Wreschner D. H. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins - cytokine receptor-like molecules. FEBS Lett., 356: 130-136, 1994.
26. Keydar, I., Chou, C. S., Hareuveni, M., Tsarfaty, I., Sahar, E., Selzer, G., Chaitchik, S., and Hizi, A. Production and characterization of monoclonal antibodies identifying breast tumor associated antigens. Proc. Natl. Acad. Sci. USA, 86: 1362-1366, 1989.
27. Mehlman, T., and Burgess, W. H. Detection and characterization of heparin-binding proteins with a gel overlay procedure. Anal. Biochem., 188: 59-163, 1990.
28. Ruff, S. J., Chen, K., and Cohen, S. Peroxovanadate induces tyrosine phosphorylation of multiple signaling proteins in mouse liver and kidney. J. Biol. Chem., 272: 1263-1267, 1997.
29. Oosterkamp, H. M., Schemer, L., Stefanova, M. C., Lloyd, K. O., and Finstad, C. Comparison of MUC1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form. Int. J. Cancer, 72: 87-94, 1997.
30. Bazan, F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA. 87: 6934-6938, 1990.
31. Pandey, P., Kharbanda, S., and Kufe, D. Assoeialion of the DF3/MUC1 breast cancer antigen with the Grb2 and the sos/ras exchange protein. Cancer Res., 55: 4000-4003, 1995.
32. Yamamoto, M., Bharti, A., Li, Y., and Kufe, D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J. Biol. Chem., 272: 12492-12494, 1997.
33. Aberle, H., Schwarts, H., and Kemler, R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell. Biochem., 61: 514-523, 1996.
34. Serres, M., Grangeasse, C., Haftek, M., Durocher, Y., Duclos, B., and Schmitt, D. Hyperphosphorylation of β-catenin on serine-threonine residues and loss of cell-cell contact induced by calyculin A and okadaic acid in human epidermal cells. Exp. Cell. Res., 231: 163-172, 1997.
35. Aplin, J. D., Hey, N. A., and Li, T. C. MUC1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Am. J. Reprod. Immunol., 35: 261-266, 1996.
36. Kramer, H., Cagan, R. L., and Zipursky, S. L. Interaction of sevenless membrane-bound ligand and the sevenless tyrosine kinase receptor. Nature (Lond.), 352: 207-212, 1991.
37. Jing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., Louis, J. C., Hu, S., Altrock, B. W., and Fox, G. M. GDNF-induced activation of the ret protein lyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell, 85: 1113-1124, 1996.
38. Vu, T. K., Hung, D. T., Wheaton, V. I., and Coughlin, S. R. Molecular cloning of a functional receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64: 1057-1068, 1991.
39. Pouyani, T., and Seed, B. PSGL-1 recognition of P-selectin is controlled by a lyrosine sulfation consensus at the PSGL-1 amino terminus. Cell, 83: 333-343, 1995.
40. Sako, D., Comess, K. M., Barone, K. M., Camphausen, R. T., Cumming, D. A., and Shaw, G. D. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell, 83: 323-331, 1995.
41. Spicer, A. P., Duhig, T., Chilton, B. S., and Gendler, S. J. Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mamm. Genome, 6: 885-888, 1995.
42. Katayose, Y., Kudo, T., Suzuki, M., Shinoda, M., Saijyo, S., Sakuri, N., Saeki, H., Fukuhara, K., Imai, K., and Matsuno, S. MUC1 specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res., 56: 4205-4212, 1996.
43. Kunkler, R. B., Bishop, M. C., Green, D. J., Pimm, M. V., Price, M. R., and Frier, M. Targeting of bladder cancer with monoclonal antibody NCRC48 - a possible approach for intravesical therapy. Br. J. Urol., 76: 81-86, 1995.
44. Kasahara, N., Dozy, A. M., and Kan, Y. W. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science (Washington DC), 266: 1373-1376, 1994.